Associate Vice President for Research and Research Compliance Officer
Research compliance at The University of Texas at Tyler is managed by the Associate Vice President for Research and Research Compliance Officer, Dr. Anna Kurdowska. The university's compliance mission is to support comprehensive programs of academic research by assuring institutional and investigator compliance with applicable regulations, policies and industry standards while engaged in scholarly activities associated with animal research, research involving recombinant DNA (rDNA) and the use of select or infectious agents. Dr. Kurdowska also oversees and assists investigators with compliance with export control laws and intellectual property policies.
Non-compliance can result in severe penalties to the institution, and in some instances, to the individual. It is the responsibility of faculty and staff to be familiar with UT Tyler policy as it relates to these research compliance areas.
Institutional Review Board (IRB)
The UT Tyler Institutional Review Board (IRB) is overseen by the Human Research Protections Program which is responsible for protecting the rights and welfare of research participants, as well as ensuring excellent scientific research is conducted ethically and in compliance with all federal, state, local regulations, and institutional policies. For more information about conducting research with human subjects, click here.
Institutional Animal Care and Use Committee (IACUC)
For more information on research involving the use of animals, contact Dr. Anna Kurdowska.
Institutional Biosafety Committee (IBC)
The Institutional Biosafety Committee (IBC) of The University of Texas at Tyler (UT Tyler) reports on matters related to the use of recombinant deoxyribonucleic acid (rDNA) technology in research and educational activities at UT Tyler. The committee is charged with ensuring full compliance with NIH Guidelines for Research Involving Recombinant DNA Molecules, referred to herein as the NIH Guidelines. For more information on research involving recombinant deoxyribonucleic acid (rDNA) technology, contact Dr. Anna Kurdowska.